All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 5%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), atezolizumab plus SoC vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.83 [0.69; 1.00]
0.83 [0.69 ; 1.00 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable progression or deaths (PFS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.82 [0.70; 0.96]
0.82 [0.70 ; 0.96 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable CRR detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [1.21; 3.17]
1.96 [1.21 ; 3.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable DORdetailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.70 [0.46; 1.08]
0.70 [0.46 ; 1.08 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 386 NA not evaluable objective responses (ORR)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.15 [0.88; 1.51]
1.15 [0.88 ; 1.51 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable AE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.34 [0.43; 12.83]
2.34 [0.43 ; 12.83 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.92 [0.63; 1.34]
0.92 [0.63 ; 1.34 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.27 [0.70; 2.27]
1.27 [0.70 ; 2.27 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.05 [0.79; 1.40]
1.05 [0.79 ; 1.40 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 850 NA not evaluable SAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.85; 1.46]
1.11 [0.85 ; 1.46 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable STRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.33 [0.99; 1.80]
1.33 [0.99 ; 1.80 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable TRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.04 [0.53; 2.03]
1.04 [0.53 ; 2.03 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.02 [0.72; 1.43]
1.02 [0.72 ; 1.43 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable TRAE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [0.60; 6.40]
1.96 [0.60 ; 6.40 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.67; 1.84]
1.11 [0.67 ; 1.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.00 [0.82; 4.92]
2.00 [0.82 ; 4.92 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.59 [0.27; 25.03]
2.59 [0.27 ; 25.03 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.61 [0.70; 9.73]
2.61 [0.70 ; 9.73 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.73 [0.31; 9.49]
1.73 [0.31 ; 9.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.01 [1.12; 3.62]
2.01 [1.12 ; 3.62 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Pruritus TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.72 [0.06; 51.51]
1.72 [0.06 ; 51.51 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Rash TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.02; 43.49]
0.86 [0.02 ; 43.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.55; 2.26]
1.11 [0.55 ; 2.26 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.08 [0.82; 1.42]
1.08 [0.82 ; 1.42 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.43 [0.81; 2.50]
1.43 [0.81 ; 2.50 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.66 [0.37; 1.17]
0.66 [0.37 ; 1.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.76 [0.81; 3.80]
1.76 [0.81 ; 3.80 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.22 [1.05; 4.68]
2.22 [1.05 ; 4.68 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.74 [0.44; 1.24]
0.74 [0.44 ; 1.24 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.54 [0.23; 1.27]
0.54 [0.23 ; 1.27 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.38 [1.03; 1.84]
1.38 [1.03 ; 1.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.25 [0.89; 1.76]
1.25 [0.89 ; 1.76 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Vomiting AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.37; 2.00]
0.86 [0.37 ; 2.00 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 10:05 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 866